Glooko
Glooko operates a cloud-based diabetes data management platform that integrates 200+ devices and major EHR systems for hospitals, clinics, and people with diabetes, and provides FDA-cleared inpatient insulin dosing through the EndoTool system acquired from Monarch Medical Technologies in 2025.
- Company typePrivate
- Founded2012
- HeadquartersPalo Alto, United States
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What Glooko does
Glooko is a Palo Alto-based digital health company that operates a cloud-based diabetes data management platform serving healthcare providers, hospitals, health systems, and people with diabetes. The platform aggregates data from more than 200 diabetes and health monitoring devices, integrates with major EHR systems including Epic, Oracle Health, and MEDITECH, and processes over 3 billion data points per month, enabling population health analytics, remote patient monitoring, and clinical decision support across the care continuum.
The product portfolio spans the outpatient Glooko Diabetes Management Platform and Glooko Web Application, a free consumer-facing Glooko Mobile App, the France-only Glooko XT remote patient monitoring product (reimbursed by the French National Health Insurance), and the inpatient EndoTool Glucose Management System acquired from Monarch Medical Technologies in September 2025. EndoTool, an FDA-cleared patient-specific insulin dosing platform using patented algorithms, was extended with the FDA 510(k)-cleared EndoTool IV Cloud in May 2026, the first FDA-cleared cloud-based insulin dosing platform for IV therapy in hospital settings. Glooko also operates a life sciences vertical supplying real-world device data and clinical research support to pharmaceutical partners including Eli Lilly, Novo Nordisk, and Sanofi.
The business model combines enterprise SaaS subscriptions to hospitals, health systems, and clinics (quote-based annual contracts) with a freemium consumer mobile app, supplemented by EndoTool inpatient software revenue and life sciences partnerships. The company sells through direct enterprise field sales, mobile app stores, and device manufacturer channel partnerships, and holds multiple top-tier security and medical device certifications (HITRUST r2, ISO 27001, SOC 2 Type II, HIPAA, GDPR, ISO 13485, EU MDR Class IIa, FDA 21 CFR Part 11). As of 2026, Glooko operates in 24+ countries across North America and Europe, serves thousands of clinics and millions of patients, and is led by CEO Mike Alvarez following a $100 million Series F financing in October 2024.
Glooko firmographics
Firmographics- Name
- Glooko
- Legal name
- Glooko, Inc.
- Website
- https://glooko.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Glooko operates a cloud-based diabetes data management platform that integrates 200+ devices and major EHR systems for hospitals, clinics, and people with diabetes, and provides FDA-cleared inpatient insulin dosing through the EndoTool system acquired from Monarch Medical Technologies in 2025.
- Ownership category
- akta.pro rank
Glooko industry classification
Industry- Product category
- Digital Health Diabetes Management Software
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)
- akta.pro secondary industry
- Endocrinology & Diabetes Telemedicine Platforms (HLALAGAD)
Keywords
Where Glooko is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Glooko business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Enterprise Software Subscriptions: Recurring SaaS revenue from hospitals, health systems, and clinics subscribing to the Glooko diabetes management platform. The company targets enterprise-level contracts with integrated delivery networks, positioning platform stickiness as a driver of recurring revenue streams.
- Mobile App (Consumer): Free Glooko Mobile App for people with diabetes drives user acquisition and ecosystem lock-in. The app syncs data from over 200 devices and enables remote collaboration with care teams.
- EndoTool Inpatient Solutions: Revenue from EndoTool Glucose Management System for hospital inpatient glycemic management, following acquisition of Monarch Medical Technologies in September 2025. FDA-cleared cloud-based insulin dosing platform for scalable hospital deployment.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | Glooko Mobile App - Free for individuals with diabetes |
| Subscription | Annual | Enterprise healthcare provider platform - Custom pricing |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Glooko product offering
Product offeringCore offering
Glooko provides a cloud-based diabetes management platform that aggregates data from over 200 diabetes and health monitoring devices, integrates directly with major EHR systems, and delivers AI-powered glycemic insights to healthcare providers and patients. Its portfolio spans the outpatient Glooko Diabetes Management Platform, the free Glooko Mobile App for patients, and the EndoTool Glucose Management System (acquired from Monarch Medical Technologies) for inpatient insulin dosing, offering an end-to-end hospital-to-home diabetes care solution.
Product overview
Glooko is a digital health company offering a connected care platform for diabetes management across the full care continuum. The portfolio consists of the outpatient Glooko Diabetes Management Platform and Glooko Web Application, the free Glooko Mobile App for people with diabetes, the inpatient EndoTool Glucose Management System (acquired from Monarch Medical Technologies in September 2025) with its cloud-based variant EndoTool IV Cloud, Glooko XT remote patient monitoring (France only), and the Glooko Transmitter hardware device. The platform aggregates patient data from more than 200 diabetes and health monitoring devices, integrates with major EHR systems, and delivers AI-powered insights for glycemic management in both outpatient and inpatient settings.
Differentiator
Problem solved
Functional benefit
Brands
- EndoTool: FDA-cleared patient-specific insulin dosing platform for inpatient glycemic management in hospital settings; developed by Monarch Medical Technologies, a Glooko company.
- Glooko XT
- Glooko Mobile App
Products and services
- Glooko Diabetes Management Platform
- Glooko Mobile App Free mobile app for people with diabetes that syncs and displays data from more than 200 devices including glucose monitors, insulin pumps, fitness trackers, and food tracking apps in one place. Provides easy-to-understand visualizations and secure sharing so users can monitor trends and remotely collaborate with their care team between appointments.
- EndoTool Glucose Management System FDA-cleared software using patented patient-specific algorithms for real-time insulin dosing in hospitalized patients. Originally developed by Monarch Medical Technologies and now part of Glooko, EndoTool is the only patient-specific insulin dosing system designed for inpatient glycemic management.
- EndoTool IV Cloud First FDA-cleared cloud-based patient-specific insulin dosing platform for intravenous insulin therapy in hospital settings. Retains the core EndoTool IV dosing algorithm while adding cloud-based functionality for more scalable deployment, centralized updates, and reduced on-premises infrastructure requirements.
- Glooko XT Remote patient monitoring platform for diabetes available exclusively in France, recognized by the French digital health agency as a certified digital medical device. Eligible for reimbursement for remote diabetes monitoring by the French National Health Insurance.
- Glooko Web Application Diabetes management web platform used in-clinic or remotely by healthcare professionals and patients. Allows viewing of patient data from compatible medical devices and other health monitoring devices and enables healthcare professionals to support treatment of diabetes through analysis and monitoring of therapy and care programs.
- Glooko Transmitter Hardware device indicated for use by healthcare professionals in health care facilities to transfer predefined data from home monitoring devices to a server database, enabling instant and secure data upload during consultations.
Quantifiable outcome
- Reduction in HbA1c levels within 3 months of Glooko use, with sustained results after one year
- +4 more outcomes
Companies that use Glooko
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
Glooko technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration13 records
AI capability3 records
Feature4 records
Glooko partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core, secondary and minor.
- MyLife Diabetes CarecoreExpanded partnership under which Glooko serves as MyLife Diabetes Care's primary data management platform for connected diabetes products. Builds on existing collaboration to support automated insulin delivery solutions and improve data accessibility for patients and healthcare teams. Partnership responds to growing adoption of connected therapy models in diabetes care. MyLife plans to strengthen its digital ecosystem using Glooko's management platform, including EndoTool for inpatient insulin dosing.
- Roche Diabetes CarecoreIntegration partnership enabling Glooko platform to connect with Roche's Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution across 12 European countries. This is reportedly the first external platform connection to Roche's Accu-Chek SmartGuide CGM. Enables patients to consolidate CGM data alongside other health and medication data in a single view. Rollout in key European markets subject to local regulatory requirements.
- Monarch Medical TechnologiescoreAcquisition of Monarch Medical Technologies, developer of EndoTool Glucose Management System. Expands Glooko's connected diabetes care platform into hospitals, strengthening inpatient glycemic management capabilities. EndoTool is FDA-cleared software using patented patient-specific algorithms for real-time insulin dosing in hospitalized patients. Glooko plans to integrate both offerings on single platform for comprehensive hospital-to-home diabetes management.
- Roche Diabetes CarecoreStrategic CGM integration expanding EMEA connectivity for Glooko's diabetes management platform
- Abbott LaboratoriescoreIntegration of Abbott's FreeStyle Libre continuous glucose monitoring (CGM) system into Glooko's platform in the United States. Allows patients to consolidate CGM data with insulin usage, exercise, diet, and other health metrics into unified view. Healthcare providers gain complete picture for clinical decision-making. Partnership covers individuals with Type 1 and Type 2 diabetes across U.S. healthcare systems.
- DexcomcorePlatform integration allowing users to connect and sync data from Dexcom CGM devices with various diabetes management devices, enabling remote collaboration with healthcare providers
- HediacoreJoint launch of personalized bolus insulin dosing support solution. Partnership combines Hedia's bolus calculator technology with Glooko's diabetes management platform to enhance outcomes for people on multiple daily insulin (MDI) therapy with precise dose recommendations
- Innovation ZedsecondaryPartnership to revolutionize injectable therapy management with digital companion apps. Integration enables connectivity for injectable therapy management within Glooko's platform
- YpsomedsecondaryDevice manufacturer partner with insulin pump and delivery systems integrated with Glooko platform
- Tandem Diabetes CarecoreDevice manufacturer partner with insulin pump integration enabling data synchronization with Glooko platform
- Eli LillysecondaryPharmaceutical partner for diabetes management solutions and potential therapeutic integrations
- SanofisecondaryPharmaceutical partner for diabetes management solutions and therapeutic integrations
- JDRF ( Breakthrough T1D)minorNon-profit partner advancing Type 1 diabetes research and awareness
- T1D ExchangeminorNon-profit partner focused on improving Type 1 diabetes care through data and research
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Glooko competitors and assessment
Company assessmentDirect peers
- mySugr (Roche Diabetes Care): Roche-owned diabetes self-management app and data platform tightly integrated with Accu-Chek meters. Directly comparable to Glooko's consumer-facing mobile app and outpatient platform; competes for the same endocrinologist and patient mindshare.
- Dexcom: Leading CGM manufacturer with its own diabetes data platforms (Dexcom Clarity, Stelo). Although also a Glooko integration partner, Dexcom competes on the data analytics layer for CGM users and has incentive to consolidate the stack.
- Glytec: Provider of the Glucommander inpatient insulin dosing software, the most direct competitor to Glooko's EndoTool IV Cloud in the hospital glycemic management space. Targets the same IDN and hospital pharmacy customers.
- DarioHealth: Digital therapeutics platform combining a smart glucose meter, mobile app, and AI-driven coaching for diabetes and other chronic conditions. Competes directly with Glooko's consumer-facing mobile experience and B2B2C employer/payer channel.
- One Drop: Consumer-facing diabetes management app and B2B platform offering glucose prediction, coaching, and connected device support. Directly comparable to Glooko Mobile in features and to Glooko's enterprise contracts in target customers.
- LifeScan: Blood glucose monitoring company (OneTouch) with a connected diabetes management platform. Competes with Glooko in aggregating and visualizing BGM data for patients and providers, particularly in retail pharmacy and self-pay channels.
Broad incumbents
- Abbott Diabetes Care: FreeStyle Libre CGM manufacturer with the LibreView and LibreLinkUp data platforms. Serves as both an integration partner to Glooko and a competitor offering device-tied diabetes data visualization for clinicians and patients.
- Tandem Diabetes Care: Insulin pump manufacturer with the t:connect diabetes management application. While a Glooko integration partner, Tandem also offers device-tied diabetes data visualization to endocrinologists, overlapping with Glooko's provider workflow.
- Medtronic Diabetes: Major insulin pump and CGM manufacturer with the CareLink diabetes management platform. Both a Glooko investor and integration partner, and a competitor offering its own end-to-end diabetes data platform to clinicians.
Emerging players
- Verily (Onduo): Alphabet life sciences subsidiary with Onduo, a virtual diabetes management program combining CGM, coaching, and clinician support. Competes for enterprise payer and provider contracts in digital diabetes management.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Glooko social profiles
Digital presenceGlooko compliance and trust
Trust signalCompliance12 records
Glooko financial estimates
Financial estimateRevenue estimate
Valuation estimate
Glooko leadership team
Management profileNumber of profiles
Profiles16 records
Glooko subsidiaries and ownership
Company hierarchySubsidiaries1 record
Glooko funding detail
Funding detailFunding overview
Funding rounds9 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Glooko M&A and investment
M&A and investmentM&A4 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Glooko
What does Glooko do?
Glooko provides a cloud-based diabetes management platform that aggregates data from over 200 diabetes and health monitoring devices, integrates directly with major EHR systems, and delivers AI-powered glycemic insights to healthcare providers and patients. Its portfolio spans the outpatient Glooko Diabetes Management Platform, the free Glooko Mobile App for patients, and the EndoTool Glucose Management System (acquired from Monarch Medical Technologies) for inpatient insulin dosing, offering an end-to-end hospital-to-home diabetes care solution.
Is Glooko a public or private company?
Glooko is a private company. It is classified as venture growth investor backed and is currently operating.
When was Glooko founded?
Glooko was founded in 2012. It employs 101 to 250 people.
Where is Glooko based?
Glooko is headquartered in Palo Alto, United States, in the North America region.
How does Glooko make money?
Three revenue lines are on record. Enterprise Software Subscriptions are the primary driver. The others are mobile App (Consumer) and endoTool Inpatient Solutions.
Who are Glooko's main competitors?
Direct peers on record are mySugr (Roche Diabetes Care), Dexcom, Glytec, DarioHealth, One Drop and LifeScan. Broad incumbents are Abbott Diabetes Care, Tandem Diabetes Care and Medtronic Diabetes. Verily (Onduo) is listed as an emerging player.
Does Glooko have an API?
Yes. Glooko offers an API and EHR Integration Portal available at developers.glooko.com. The portal provides API Terms of Service for developers. Specific technical details such as API type (REST, GraphQL, webhooks), authentication method, rate limits, versioning, or sandbox availability are not stated in the available source materials. Developer documentation is at developers.glooko.com.
What industry is Glooko in?
Glooko's product category is Digital Health Diabetes Management Software. Its primary akta.pro industry code is HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators), with a secondary code of HLALAGAD, Endocrinology & Diabetes Telemedicine Platforms. Its SIC code is 8011.